COMP <GO>
MMED vs LLY // ALTMAN Z-SCORE & DEBT/EQUITY
MiniMed Group Inc. (NASDAQ) VS. Eli Lilly and Company (NYSE) • 15-METRIC TALLY: MMED 2
— LLY 12
▲ ALTMAN Z-SCORE & DEBT/EQUITY LEADER: LLY
LAST: $18.28 (-5.04%) • MKT CAP: $5.42B
balance-sheet
4.82
LAST: $1,417.54 (+3.19%) • MKT CAP: $1.33T
balance-sheet
9.29
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (MMED VS. LLY)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | MMED | LLY | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 54.20% | 83.64% | -29.44 | LLY | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -3.90% | 32.36% | -36.26 | LLY | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 36.4x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -7.75% | 2.30% | -10.05 | LLY | /fcf-yield <GO> |
| Operating Margin | -6.10% | 40.21% | -46.31 | LLY | /operating-margins <GO> |
| Net Profit Margin | -10.70% | 31.90% | -42.60 | LLY | /net-margins <GO> |
| Revenue Growth (YoY) | 14.30% | 45.51% | -31.21 | LLY | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.49% | -0.49 | LLY | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity ACTIVE | 4.82 | 9.29 | -4.47 | LLY | /balance-sheet <GO> |
| Piotroski F-Score Quality | 5/9 | 9/9 | -4.00 | LLY | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 7.10% | 6.77% | +0.33 | LLY | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 43.8 | 77.9 | -34.06 | LLY | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.05 | 0.51 | +0.54 | MMED | /macro-sensitivity <GO> |
| Forward P/E Multiple | 24.0x | 26.3x | -2.25 | MMED | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $5.42B | $1.33T | -$1.33T | LLY | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | MMED REV | LLY REV | MMED GROSS % | LLY GROSS % | MMED FCF | LLY FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $3.10B | $65.18B | 54.2% | 83.0% | -$420.0M | $16.81B |
| FY 2024 | $2.71B | $45.04B | 56.3% | 81.3% | -$53.0M | $8.82B |
| FY 2023 | $2.47B | $34.12B | 44.0% | 79.3% | -$70.1M | $4.24B |
| FY 2022 | — | $28.54B | — | 76.8% | — | $7.59B |
| FY 2021 | — | $28.32B | — | 74.2% | — | $7.37B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
MMED // BETA 1.05
LLY // BETA 0.51